Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Norethindrone
Drug ID BADD_D01585
Description Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins.[A10367] It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol].[A10367] Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency,[A188075] and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.[L10439]
Indications and Usage For the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
Marketing Status Prescription; Discontinued
ATC Code G03AC01; G03DC02
DrugBank ID DB00717
KEGG ID D00182
MeSH ID D009640
PubChem ID 6230
TTD Drug ID D0GL7U
NDC Product Code 60870-0235; 68180-876; 69238-1583; 68462-303; 50102-300; 68180-877; 52544-629; 0378-7272; 16714-440; 49452-4862; 65862-925; 51862-886; 65162-475; 53002-2687; 63187-748; 70518-3113; 0378-7292; 42291-650; 16714-441; 50090-3235; 50102-100; 51862-884; 50102-200; 68462-305; 71205-526; 30007-829
Synonyms Norethindrone | Norpregneninolone | Norethisterone | 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)- | Ethinylnortestosterone | Conceplan | Micronor | Norlutin | Nor-QD | Nor QD | NorQD | Norcolut | Norcolute | Norethindrone, (1 beta)-Isomer | Monogest
Chemical Information
Molecular Formula C20H26O2
CAS Registry Number 68-22-4
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.001--Not Available
Acne23.02.01.001--Not Available
Adenoma benign16.02.02.001--Not Available
Alopecia23.02.02.001--
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anovulatory cycle21.01.01.011; 05.05.01.017--Not Available
Asthenia08.01.01.001--Not Available
Benign hepatic neoplasm16.06.01.001; 09.04.01.001--Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Breast enlargement21.05.04.001--Not Available
Breast feeding26.05.01.001--Not Available
Breast pain21.05.05.003--
Breast tenderness21.05.05.004--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral thrombosis24.01.04.003; 17.08.01.006--Not Available
Uterine cervical erosion21.06.01.006--Not Available
Chloasma18.08.02.002; 23.05.01.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspepsia07.01.02.001--
Embolism arterial24.01.01.014--
Erythema multiforme23.03.01.003; 10.01.03.015--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages